emtricitabine/tenofovir (Truvada, TDF/FTC, Descovy)
Jump to navigation
Jump to search
Introduction
Tradenames:
- Truvada (Generic FDA-approved June 2017)[7]
- Descovy emtricitabine 200 mg + tenofovir alafenamide
Indications
- HIV-1 infection
- pre-exposure prophylaxis
- up to 75% effective
- not-effective in women[4]
Dosage
QD dosing
Tabs:
- Truvada: emtricitabine (FTC) 200 mg, tenofovir 300 mg QD
- Descovy: emtricitabine 200 mg, tenofovir alafenamide QD[8]
Storage
- store in orginal container
- original container has a desiccant[6]
Mechanism of action
- combination anti-retroviral agent
- injected tenofovir 22 mg/kg/emtricitabine 20 mg/kg prevented HIV infection in rhesus monkeys
Notes
Manufacturer: Gilead Sciences
More general terms
Components
References
- ↑ Prescriber's Letter 12(2): 2005 New Drugs Approved by the FDA in 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210216&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Prescriber's Letter 13(5): 2006 Truvada (Emtricitabine/Tenofovir) and HIV prevention Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220508&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Grant RM et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010 Nov 23; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21091279 <Internet> http://dx.doi.org/10.1056/NEJMoa1011205
Michael NL. Oral preexposure prophylaxis for HIV - Another arrow in the quiver? N Engl J Med 2010 Nov 23; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21091280 <Internet> http://dx.doi.org/10.1056/NEJMe1012929
Prescriber's Letter 18(1): 2011 Truvada for Pre-Exposure Prophylaxis of HIV Infection Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=270106&pb=PRL (subscription needed) http://www.prescribersletter.com - ↑ 4.0 4.1 FHI statement on the FEM-PrEP HIV prevention study [press release]. Durham, NC: Family Health International; Apr 18 , 2011 http://www.fhi.org/en/AboutFHI/Media/Releases/FEM-PrEP_statement041811.htm
Perrone Matthew FDA panel backs first pill to block HIV infection Associated Press, May 10, 2012 http://news.yahoo.com/fda-panel-backs-first-pill-block-hiv-infection-225920976--finance.html - ↑ FDA News Release: July 16, 2012 FDA approves first drug for reducing the risk of sexually acquired HIV infection http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm
- ↑ 6.0 6.1 Prescriber's Letter 21(6): 2014 Oral Meds to Keep in Original Containers Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300622&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 7.0 7.1 Lowes R FDA Approves First Generic Truvada in US Medscape - Jun 09, 2017. http://www.medscape.com/viewarticle/881368
- ↑ 8.0 8.1 FDA News Release. Oct 3, 2019 FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic